20 Jan 12

Recruiters are very busy people, and typically have little time to read and select CVs for any given role. For them it’s a filtering process, often starting with a pile of CV’s and throwing out the bad ones before reading in more detail, the ones that are left. Therefore your task is NOT to get thrown out with the bathwater, and ensure that your CV is one of the ones that makes it past the first cull!
Mike Wood

04 Oct 11

We recently ran a survey to ask people about the work they do when they are on vacation. It makes interesting reading!
Mike Wood

03 Oct 11

NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
NICE

25 Aug 11

How common is it to work during your vacation? - Take our short survey.
Mike Wood

17 Aug 11

Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter

04 Aug 11

Find out about the latest jobs that match your search - automatically.
Mike Wood

14 Apr 11

Want to know which Pharma companies are on Twitter? - here's a list..
Mike Wood

24 Feb 11

After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter

22 Feb 11

Social networking sites such as Facebook, Linkedin and Twitter are all the rage – there’s no escaping them, they’re everywhere – even in the workplace, and whether you like it or not, they’re not going away.
Catherine Gutsell, CK Group

18 Feb 11

If you've got your self an interview for the perfect job - well done! Now comes the hard part, and you only get one chance. So, here's a simple check list of things that should help you keep your cool and allow you to concentrate on sailing through the interview
Mike Wood

07 Feb 11

If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting. However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
Mike Wood

11 Nov 10

As patients and prescribers increasingly move online for their information, how can pharma engage these audiences by incorporating digital marketing into their current plans?
Mike Wood

07 Sep 10

A new book by Rebecca J. Anderson
Mike Wood

23 Jul 10

If the nation’s recruiters received a pound for every time they’d interviewed a candidate that looked good on paper but disappointed in practice, there’d currently be an awful lot of recruiters in the process of relocating to the Caribbean.
Max Golby / Mike Wood

20 May 10

Economic uncertainty has fueled a growing trend toward self-employment and entrepreneurialism with one-in-five respondents worldwide now working outside the traditional employment relationship, and 50 percent saying that they would like to do so, according to the latest survey results from workforce solutions leader Kelly Services®.
Editor

09 Apr 10

Until recently, pharmaceutical companies paid little attention to the process of maximising their data through publications. Today, several pharma firm and even consumer companies are beginning to recognise publications planning as an integral part of the marketing matrix. It now forms part of the overall communications strategy, adopted not only to raise awareness of a product and its key messages, but also to provide an evidence base for all other communication activities for the product.
Dr Sabah Al-Lawati

01 Apr 10

With an age of the expiry cliff approaching and a move towards contracted research organizations, is this the end of pharmaceutical companies as we know them? And are job cuts an inevitable reaction to this new business style?
Emma Naylor

30 Mar 10

I am a lapsed pharma marketer and as such I still like to read the industry press. It is striking that almost every article is about how the industry has to change to meet the needs of the NHS, to add value.
David Southern

29 Mar 10

Urgent meetings are being held by the financial leaders of American Healthcare companies in the wake of Obama’s Healthcare Reform being passed 219 – 212 in the House of Representatives.
Victoria Poole

26 Nov 09

I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
Mike Wood

17 Nov 09

We're having a fascinating day at the Financial Times Global Pharmaceutical and Biotechnology conference on London.
Paul Hartigan

28 Oct 09

A difficult economic climate breeds desperation. This is perhaps one of the most plausible explanations for the apparent behaviour of several unethical recruiters in the marketplace.
Max Golby - PharmiWeb Field Reporter

27 Oct 09

Whatever happened to the days of donning your best suit and tie and going out and looking for a job? Knocking on doors and meeting prospective employers, dazzling them with your wit, intelligence and enthusiasm. Unfortunately that is not possible in today’s society.
Trevor Abbott - PharmiWeb Field Reporter

28 Sep 09

A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen

15 Jun 09

Unless it paints the right picture you’re letting the side down!

In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who ‘piggy back’ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD

12 Jun 09

Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.
Datamonitor

11 Jun 09

Dr Wolfgang Wein, Executive Vice-President of Merck Serono’s Oncology Business comments on the recent final appraisal determination by NICE paving the way for its leading oncology product Erbitux to benefit UK mCRC patients.
Olwen Glynn Owen - Pharmiweb Field reporter

05 Jun 09

Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends
Priyanka Adhikari - Datamonitor

01 Jun 09

The Department of Health is determined to improve commissioning, and it will do whatever it takes to make it happen. That is the message that senior departmental officials sent to practice based commissioners last week at a National Association of Primary Care conference in London.
Miriam George

01 Jun 09

The time has arrived for primary care trusts to shed their provider functions, and it is causing considerable angst in the community services sector. It was inevitable that sooner or later, the split would have to happen, but now the race is on to decide what organisation model they want to adopt: foundation trust or social enterprise?
Miriam George